Real life adjuvant chemotherapy uptake and survival in patients with non-small cell lung cancer after complete resection
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- Klíčová slova
- Non-small cell lung cancer, adjuvant chemotherapy uptake, real-world study, survival,
- MeSH
- adjuvantní chemoterapie * metody statistika a číselné údaje MeSH
- analýza přežití MeSH
- cisplatina terapeutické užití MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mezioborová komunikace MeSH
- nádory plic * farmakoterapie mortalita patologie terapie MeSH
- nemalobuněčný karcinom plic * farmakoterapie mortalita patologie chirurgie MeSH
- pneumektomie * metody statistika a číselné údaje MeSH
- protinádorové látky terapeutické užití MeSH
- retrospektivní studie MeSH
- senioři MeSH
- spotřeba léčiv statistika a číselné údaje MeSH
- staging nádorů MeSH
- vinorelbin terapeutické užití MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika epidemiologie MeSH
- Názvy látek
- cisplatina MeSH
- protinádorové látky MeSH
- vinorelbin MeSH
OBJECTIVES: Adjuvant chemotherapy (AC) in non-small cell lung cancer (NSCLC) has become a standard of care in patients with stages IIA, IIB, and IIIA after complete tumor resection. Utilization and outcome of AC in routine practice is described in a few studies, with non-conclusive results. MATERIALS AND METHODS: This retrospective study included consecutive patients with NSCLC who underwent curative-intent surgery. Data of AC uptake in stages IB (tumor of ≥4 cm in diameter), II, and IIIA, and reasons of AC omission were evaluated according to medical records. Mortality risk among patients treated with surgery (only) and different types of AC in routine practice was compared. RESULTS: AC was applied to 79% of patients with stages IB (tumor of ≥4 cm in diameter), II, and IIIA, and was associated with an improved median of overall survival (HR = 0.69; 95% CI = 0.44-1.06). Significantly longer survival was achieved in the sub-group treated with platinum and oral vinorelbine (HR = 0.575, 95% CI = 0.339-0.974), and the longest survival was among patients treated with oral vinorelbine and cisplatin (HR = 0.371, 95% CI = 0.168-0.820). CONCLUSIONS: AC utilization should be based on co-operation between surgeons, pneumo-oncologists, and patients. Rational use of AC offers better survival in routine practice.
b Department of Surgery University Hospital Olomouc Olomouc Czech Republic
c Department of Molecular Pathology Palacky University Olomouc Czech Republic
Department of Respiratory Medicine University Hospital Olomouc Olomouc Czech Republic
Citace poskytuje Crossref.org
